Doxazosin treatment chronic congestive heart failure results randomized double-blind placebo-controlled study study effects once-daily administration oral doxazosin patients chronic congestive heart failure CHF stabilization period weeks digitalis diuretics patients chronic CHF doxazosin placebo double-blind fashion Patients underwent weekly dose adjustments doses doxazosin mg placebo weeks additional weeks doses study drugs Treatment groups respect symptoms heart failure indexes quality life ventricular function frequency type arrhythmia adverse events mortality rates Doxazosin mg favorable trend investigators patients assessments symptomatic change Doxazosin level voluntary submaximal exercise favorable trend left ventricular ejection fraction increase baseline value placebo NS steady-dosing period patients doxazosin significant reduction ventricular arrhythmias morbid mortal cardiac events episodes heart failure severe discontinuation study myocardial infarction death Doxazosin major side effects frequency minor treatment-related side effects placebo NS 